J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration

Bayer emphasizes Johnson & Johnson’s experience in the cardiovascular field as key asset of the deal. NDA submission for the factor Xa inhibitor is anticipated in 2007.